Have you ever visited a health facility but ended up getting disappointed not because the staff was less caring of equipment deprived of, but because of the limited scope of knowledge. This naturally would make one sink into desperation. According to Paul Mampilly, this is just about to come to an end with Myriad Genetics. This is a healthcare institution that is centrally focused on developing precision medicine. In crystal clear terms, Precision Medicine is a personalized treatment given to patient’s subject to their DNA structure and those that have proven to work in their body anatomy perfectly.
If physicians are to achieve this, it will be super easy to manage fatal diseases such as Alzheimer, arthritis, Parkinson and many other heart conditions. Myriad Genetics is just about to make this a reality as it currently has invested in research. Wouldn’t it so amazing to have personalized healthcare treatment options, drugs, and management of diseases. Conventionally, this over US$1.7 billion worth company has been dealing with the diagnosis and treatment of many types of cancers. However, they have realized cell mutations are a different subject to someone’s genetic composition. They have then gone into research on precision medicine to identify effective ways of handling patients and determine personalized care.
About Paul Mampilly
Paul Mampilly is a finance expert. However, he has admirable knowledge in a number of fields and has invested his time into research attempting to find effective ways of managing daily challenges and issues. Following his financial knowledge of wealth, he has written many resourceful articles and publication especially in matters of finance, business, medicine, technology, stock exchange and many other where he finds opportunities for business.
About Paul Mampilly, he studied Finance at the Fordham University where he graduated in 1991. He was employed by the Bankers Trust, Wall Street and later worked for Kinetic Asset Management, a hedge fund manager, fund of US$ 6 billion and grew it to US$ 25 billion. Apparently, Paul Mampilly is the Senior Editor at Banyan Hill Publishing Firm and is the founder of Profits Unlimited. He written finance publications for Rapid Profit Trader, The $10 Million Portfolio and True Momentum.